Cosmos Pharmaceutical Corp (3349) Stock Price & News

3349:TYO

Cosmos Pharmaceutical Corp

¥6,301.00

-0.41%

(-26.00) 1D

Oct 8, 11:30:00 AM GMT+9 · JPY

All symbols

	Symbol	Price	Change	% Change

Next call in 5 days

Tue, Oct 13, 12:00 AM

Fiscal period

Q1 2027

EPS / Est. (JPY)

- / -

Revenue / Est. (JPY)

- / 291.21B

Fiscal Q1 2027 earnings call

Waiting for the earnings call

At a glance: upcoming earnings

Insights from the latest news and reports

Previous reportsAll values in JPY

Loading Previous Earnings...

All values in JPY	Aug 2025	Nov 2025	Feb 2026	May 2026
Revenue	272.39B	264.78B	273.20B	289.20B
Cost of goods sold	215.22B	209.07B	216.15B	229.46B
Cost of revenue	215.22B	209.07B	216.15B	229.46B
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	45.64B	46.57B	45.83B	26.43B
Operating expense	45.64B	46.57B	45.83B	49.08B
Total operating expenses	260.86B	255.64B	261.97B	278.54B
Operating income	11.54B	9.14B	11.23B	10.66B
Other non operating income	627.00M	801.00M	667.00M	695.00M
EBT including unusual items	12.09B	9.58B	11.96B	10.60B
EBT excluding unusual items	12.08B	9.85B	11.81B	11.12B
Income tax expense	3.92B	3.10B	3.86B	1.30B
Effective tax rate	32.40%	32.35%	32.26%	12.26%
Other operating expenses	-	-	-	-
Net income	8.17B	6.48B	8.10B	9.30B
Net profit margin	3.00%	2.45%	2.96%	3.21%
Earnings per share	-	-	-	-
Interest and investment income	27.00M	19.00M	16.00M	12.00M
Interest expense	-110.00M	-107.00M	-107.00M	-257.00M
Net interest expenses	-83.00M	-88.00M	-91.00M	-245.00M
Depreciation and amortization charges	-	-	-	22.64B
EBITDA	17.09B	15.00B	16.79B	16.81B
Gain or loss from assets sale	-	-	-	-

Finance